1Jemal A, Siegel R, Ward E, et el. Cancer statistics,2008 [J]. CA Canc- er J Clin,2008 ,58 :71-96.
2Cameron JL, Coleman J, et al. One thousand consecutive pancIeati- )duodenectomies [J]. Ann Surg,2006,244( 1 ) : 10-15.
3Abrams Pu A. Radiotherapy in the adjuvant management of pancreatic adenocarinoma[J]. Semin Onco1,2005 ,32 :30.
4Zhang Y, Banerjce S, Wang Z, et aL Antitumor activity of epidermal growth factor vceptor-rdated protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer [J]. Cancer Res,2006,66 : 1025-1030.
5Mendelsohn J, Baselga J. Status of epidermal growth fact or receptor an- tagonists in the biology and treatment of cancer [J] J Clin Oncol, 2003,21 (14) :2787-2799.
6Cunningham D, Humblet Y, Siena S, et 81. Cetuximab monothempy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med,2004,351:337-345.
7Overholser JP, Prewett MC, Hceper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xcnograft in nude mice [J]. Cancer, 2000,89 : 74-82.
8Baumann M, Krause M. Targeting the epidermal ga'owth factor receptor in radiotherapy: radiobiologieal mechanisms, predinical and clinical re- sults [J]. Radiother Oneo1,2004 ,72 :257-266.
9Xiong HQ, Rosenberg A, LoBuglio A, et aL Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor,in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial(J). J Clin 0ncol,2004,22:2610-2616.
10Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer:past,present and the fumre[J]. JOP, 2007,8:4-15.
9Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus tit-uximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [ J ]. N Engl J Med,2003,346:235 - 242.
10Burton C,Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy[ J]. N Engl J Med, 2003,348 (26) : 2690 - 2691.
